<DOC>
	<DOCNO>NCT01872819</DOCNO>
	<brief_summary>This clinical trial use laboratory test call high throughput sensitivity assay plan treatment patient relapse refractory acute myeloid leukemia . The aim try identify drug may effective kill leukemia cell patient cure conventional chemotherapy . This assay test multiple drug simultaneously patient 's donate blood sample . The goal use laboratory assay best match drug patient 's disease .</brief_summary>
	<brief_title>Treatment Relapsed/Refractory AML Based High Throughput Drug Sensitivity Assay</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To obtain result high throughput drug sensitivity assay within 10 day , procure drug within 14 day initiate treatment within 21 day . SECONDARY OBJECTIVES : I . To achieve response ( cytoreduction least partial response ) great expect comparable refractory patient population salvage regimen . OUTLINE : A patient receives drug intervention base result high throughput sensitivity assay . This assay best match drug patient 's disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia World Health Organization ( WHO ) criterion ( except acute promyelocytic leukemia ) , acute leukemias ambiguous lineage WHO criterion , myelodysplastic syndrome refractory anemia excess blast ( RAEB ) 2 WHO classification advance myeloproliferative neoplasm &gt; = 10 % blast bone marrow peripheral blood , include chronic myelomonocytic leukemia ( CMML ) 2 WHO classification fail 2 induction initial diagnosis fail &gt; = 2 salvage regimen relapse acute myeloid leukemia ( AML ) Patients 1st remission &gt; = 1 year must receive cytotoxic chemotherapy salvage regimen Eastern Cooperative Oncology Group ( ECOG ) performance status 0 3 Expectation obtain 100 million blast blood and/or marrow ( example , circulate blast count 5,000 great ) Bilirubin = &lt; 1.5 x institutional upper limit normal ( IULN ) unless elevation thought due Gilbert 's syndrome , hemolysis , hepatic infiltration hematologic malignancy Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum pyruvate glutamate transaminase ( SPGT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x IULN , unless elevation thought due hepatic infiltration hematologic malignancy Alkaline phosphatase = &lt; 2.5 X ULN Serum creatinine = &lt; 2.0 mg/dL Stable improve appropriate antimicrobial therapy infection , without ongoing fever Informed consent Willing use contraception No concomitant treatment leukemia No active cancer require systemic chemotherapy radiation Significant organ compromise increase risk toxicity mortality Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>